|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 28, 2016 ) Publisher's, 'Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Pipeline Review - 2016', provides an overview of the Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR)'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the pipeline therapeutic landscape of Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR)
- The report provides overview of Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR)'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR)'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Ask for Sample Report @ www.reportsweb.com/inquiry&RW0001242091/sample
Table of Content: An Overview
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) Overview 7
Therapeutics Development 8
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Stage of Development 8
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Therapy Area 9
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Indication 10
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Ask for Discount on Report @ www.reportsweb.com/inquiry&RW0001242091/discount
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Companies 13
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Universities/Institutes 15
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development 22
Alchemia Limited 22
AstraZeneca Plc 23
Carmot Therapeutics, Inc. 24
Diabetica Limited 25
Longevity Biotech, Inc 26
Novo Nordisk A/S 27
Sanofi 28
Zealand Pharma A/S 29
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles 30
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001242091/buy/3500
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
